SQ Innovation's Lasix ONYU Receives CE Marking Approval, Advances Toward European Market Authorization

Key Takeaways

• Lasix ONYU receives CE marking certification under EU Medical Device Regulation, confirming safety and performance compliance
• European Medicines Agency accepts centralized procedure review based on technical innovation, expediting market authorization
• Regulatory milestones advance SQ Innovation’s international expansion strategy for the innovative medical device

---

SQ Innovation achieved two significant regulatory victories for its Lasix ONYU medical device on April 28, 2026, securing CE marking certification and European Medicines Agency (EMA) centralized procedure acceptance.

The Burlington, Massachusetts-based company announced that Lasix ONYU has received CE marking under the EU Medical Device Regulation (MDR 2017/745), confirming the device meets General Safety and Performance Requirements (GSPRs). This certification represents a critical milestone in the company’s international market authorization strategy.

Regulatory Pathway Accelerated

Simultaneously, the EMA confirmed Lasix ONYU’s eligibility for centralized procedure review based on technical innovation. This acceptance expedites the European market authorization process, potentially reducing time-to-market across EU member states.

The centralized procedure allows SQ Innovation to submit a single marketing authorization application that, once approved, grants market access across all 27 EU countries plus Iceland, Liechtenstein, and Norway.

Market Impact and Innovation

CE marking under the stringent MDR framework demonstrates Lasix ONYU’s compliance with enhanced safety and clinical evidence requirements that took effect in 2021. The regulation demands more rigorous clinical data and post-market surveillance compared to previous directives.

The EMA’s recognition of technical innovation suggests Lasix ONYU offers novel therapeutic approaches that could address unmet medical needs in European markets. This designation often correlates with expedited review timelines and enhanced regulatory support.

Strategic Implications

These regulatory achievements position SQ Innovation to capitalize on European medical device markets while building momentum for potential approvals in other international jurisdictions. The company’s systematic approach to regulatory compliance demonstrates commitment to meeting global standards for medical device safety and efficacy.

The dual regulatory wins provide SQ Innovation with multiple pathways to European market entry, potentially accelerating patient access to Lasix ONYU technology across the continent.

---

Frequently Asked Questions

What does CE marking mean for Lasix ONYU?

CE marking certifies that Lasix ONYU meets EU Medical Device Regulation safety and performance requirements, allowing legal marketing across European Economic Area countries.

When will Lasix ONYU be available in Europe?

While CE marking enables immediate marketing, the EMA centralized procedure timeline varies but typically takes 210 days for standard applications, potentially shorter given the technical innovation designation.

How does centralized procedure benefit patients?

EMA centralized procedure provides unified approval across all EU member states simultaneously, ensuring consistent access and avoiding country-by-country authorization delays.